Pancreatic transplantation: Beta cell replacement

被引：2

作者：

Bigam D.L. ^{[1
]}

Shapiro A.M.J. ^{[1
]}

机构：

[1] University of Alberta Hospital, Edmonton, Alta. T6G 287

来源：

Current Treatment Options in Gastroenterology | 2004年 / 7卷 / 5期

关键词：

Tacrolimus; Chronic Pancreatitis; Sirolimus; Main Drug Interaction; Islet Transplantation;

D O I：

10.1007/s11938-004-0046-9

中图分类号：

学科分类号：

摘要：

Diabetes is a leading cause of morbidity and mortality worldwide. Complications of diabetes including renal failure, retinopathy, neuropathy, and cardiovascular disease limit both survival and quality of life. Pancreatic transplantation can restore euglycemia thereby stabilizing or even reversing secondary complications of diabetes as well as improving quality of life particularly in patients with labile diabetes. Recent evidence also shows an improved survival in diabetic patients that undergo pancreatic transplantation when combined with a kidney transplant. Pancreatic transplantation should more properly be referred to as beta cell replacement as the field today encompasses both whole organ and islet cell transplantation. We have outlined herein the indications and contraindications to islet or whole organ pancreas transplantation and we have described periprocedure care and short- and long-term prognosis. Copyright © 2004 by Current Science Inc.

引用

页码：329 / 341

页数：12

共 35 条

[11]

Humar A., Khwaja K., Ramcharan T., Et al., Chronic rejection: The next major challenge for pancreas transplant recipients, Transplantation, 76, pp. 918-923, (2003)

[12]

Ryan E.A., Shandro T., Green K., Et al., Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation, Diabetes, 53, pp. 955-962, (2004)

[13]

Lakey J.R., Burridge P.W., Shapiro A.M., Technical aspects of islet preparation and transplantation, Transpl. Int., 16, pp. 613-632, (2003)

[14]

Lakey J.R., Kneteman N.M., Rajotte R.V., Et al., Effect of core pancreas temperature during cadaveric procurement on human islet isolation and functional viability, Transplantation, 73, pp. 1106-1110, (2002)

[15]

Owen R.J., Ryan E.A., O'Kelly K., Et al., Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: Radiologic aspects, Radiology, 229, pp. 165-170, (2003)

[16]

Shapiro A.M., Lakey J.R., Ryan E.A., Et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunoppressive regimen, N. Engl. J. Med., 343, pp. 230-238, (2000)

[17]

Ryan E.A., Lakey J.R.T., Paty B.W., Et al., Successful islet transplantation: Continued insulin reserve provides long-term glycemic control, Diabetes, 51, pp. 2148-2157, (2002)

[18]

Ryan E.A., Lakey J.R.T., Rajotte R.V., Et al., Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol, Diabetes, 50, pp. 710-719, (2001)

[19]

Bigam D.L., Hemming A.W., Sanabria J.R., Et al., Innominate artery interposition graft simplifies the portal venous drainage method of pancreas transplantation, Transplantation, 68, pp. 314-315, (1999)

[20]

Venstrom J.M., McBride M.A., Rother K.I., Et al., Survival after pancreas transplantation in patients with diabetes and preserved kidney function, Jama, 290, pp. 2817-2823, (2003)

← 1 2 3 4 →